ArticleFrontiers in cellular and infection microbiology2025
SOCS3 and IL-6 mRNA levels in PBMC enhance the early prediction for patients with acute-on-chronic hepatitis B liver failure receiving glucocorticoid therapy.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Research advances in immune and metabolic dysregulation in the diagnosis and treatment of acute-on-chronic liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Association of ANXA3 methylation with clinical outcomes of glucocorticoid therapy in patients with hepatitis B virus-related acute-on-chronic liver failure.Scientific reports · 2026Article
- Epstein-Barr virus reactivation triggers selective IL-6/IL-10 axis inflammation and CD3Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Early prediction is essential in hepatitis B virus-related acute-on-chronic liver failure (ACHBLF) patients receiving glucocorticoid therapy. Interleukin (IL)-6 is the main factor of cytokine storm that occurs in ACHBLF. IL-6 and suppressors of cytokine signaling 3 (SOCS3) may be associated with the prognosis of patients. Peripheral blood mononuclear cells (PBMCs), which are related to the immune response and inflammation of patients, are often used as materials for searching for biomarkers to predict ACHBLF. We aimed to determine serum cytokines levels and to evaluate the prediction value of SOCS3 and IL-6 mRNA levels in PBMC for ACHBLF patients with glucocorticoid therapy. Methods: Eighty-five patients with ACHBLF, fifty with pre-ACHBLF, fifty with CHB and thirty healthy controls (HCs) were enrolled. ACHBLF and pre-ACHBLF patients (n=135) received standard medical treatments (SMT) and 93 of them treated with glucocorticoids (SMT+GC). Serum cytokines levels, SOCS3 and IL-6 mRNA levels in peripheral blood mononuclear cells (PBMCs) were quantified. Results: Serum IL-6, IL-1ß, IL-18 and TNF-α levels of non-survivors with glucocorticoid therapy were significantly higher than that of survivors. Serum IL-10 levels in the survivors with glucocorticoid therapy were significantly increased. The analysis of variable importance shows that IL-6 ranks first. SOCS3 and IL-6 mRNA levels in PBMCs were significantly higher in ACHBLF patients than those in pre-ACHBLF patients (p=0.0158; p=0.0421). Non-survivors showed significantly lower SOCS3 levels (p=0.0084) and higher IL-6 levels (p<0 .0001) than survivors in ACHBLF patients. Non-survivors in patients receiving GC therapy had significantly lower SOCS3 levels (p=0.0002) and higher IL-6 levels (p<0 .0001) than survivors.SOCS3 and IL-6 mRNA levels were predictors for 90-day prognosis of patients receiving GC therapy (p=0.003; p=0.002). AUC of MELD score+SOCS3+IL-6 was 0.887 (95%CI, 0.818-0.955) and the optimal cut-off value was 0.29, with sensitivity of 93.3%, specificity of 74.6%. Patients receiving GC therapy with MELD score+SOCS3+IL-6=0.29 had a higher risk of poor prognosis (p<0 .0001). Survival rate in the SMT+GC group was higher than that in the SMT group (p=0.0350). Discussion: Glucocorticoid treatment could reduce the mortality of ACHBLF. SOCS3 and IL-6 mRNA combined with MELD score could be used to predict for ACHBLF patients receiving glucocorticoid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.